The aim and purpose of the Nordic study group for myeloproliferative neoplasms (NMPN) is to promote a basis for collaboration among the Scandinavian countries with the aim of providing better treatment for patients with myeloproliferative neoplasms such as polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF).
This is achieved through the performance of phase I-II studies of new treatment modalities, and randomized phase III-IV trials in collaboration with other European working groups as well as carrying out well-conducted epidemiological studies which are possible in Scandinavia due to the numerous nationwide health registers of high quality and validity. Furthermore, evidence-based clinical care programmes concerning the MPNs and eosinophilia are updated on a regular basis.
The group has evolved since its creation in 2005 and now has members from all Nordic countries.
Christen Lykkegaard Andersen, Associate Professor, MD, PhD
Chairman of the NMPN Study Group